Arcus Biosciences, Inc. 8-K

What Happened Arcus Biosciences, Inc. (RCUS) filed an 8-K on June 12, 2026, reporting the results of its annual meeting of stockholders. Voters elected four Class II directors to serve until the 2029 annual meeting, ratified Ernst & Young LLP as the company’s independent registered public accounting firm for fiscal 2026, and approved the advisory “say-on-pay” vote on executive compensation.

Key Details

• Director elections (Class II, term to 2029):
  • Dietmar Berger, M.D., Ph.D.: For 85,949,508; Withheld 18,338,022; Broker non-votes 13,573,227
  • David Lacey, M.D.: For 85,974,583; Withheld 18,312,947; Broker non-votes 13,573,227
  • Nicole Lambert: For 92,653,341; Withheld 11,634,189; Broker non-votes 13,573,227
  • Johanna Mercier: For 85,941,754; Withheld 18,345,776; Broker non-votes 13,573,227
• Auditor ratification (Proposal 2): Ernst & Young LLP ratified — For 112,905,582; Against 4,767,430; Abstentions 187,745.
• Advisory approval of executive compensation (say-on-pay, Proposal 3): For 94,920,421; Against 9,337,368; Abstentions 29,741; Broker non-votes 13,573,227.
• The Form 8-K was signed by CEO Terry Rosen, Ph.D., on June 12, 2026.

Why It Matters These votes confirm the company’s board composition and auditor for the coming year and show majority shareholder support for executive pay as disclosed in the proxy. Ratification of Ernst & Young keeps continuity in external audit oversight; the say-on-pay approval is advisory but signals general investor acceptance of compensation practices. Broker non-votes indicate a portion of shares held by brokers or intermediaries did not vote on certain matters, which can affect vote totals for non-routine proposals. No management departures or material financial disclosures were announced in this filing.